SGLT Inhibitors Protect the Heart and Kidneys: Why Is Type 1 Diabetes Still the Exception?

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a lack of biological interest. Instead, diabetic ketoacidosis (DKA), including euglycemic DKA, remains the major obstacle separating promising benefits from broader clinical use.

Table of Contents

• Why SGLT inhibition is attractive in type 1 diabetes
• The heart and kidney rationale
• Why DKA remains the central safety barrier
• What safer use would require
• Conclusion
• Frequently Asked Questions

Why SGLT Inhibitors in Type 1 Diabetes Remain Compelling

Sodium-glucose cotransporter inhibitors reduce renal glucose reabsorption, increasing glucose excretion through the urine. Importantly, this mechanism does not depend on insulin. That feature initially made SGLT inhibitor therapy for type 1 diabetes an attractive research target.

Clinical trials have provided reasons for continued interest. SGLT inhibition added to insulin can modestly improve A1C while also reducing body weight and, in some patients, insulin requirements. A 2025 systematic review and meta-analysis found an average A1C reduction of about 0.40 percentage points and a body-weight reduction of approximately 3.3 kg compared with placebo. The analysis, published in The Journal of Clinical Endocrinology & Metabolism, also highlights the safety considerations that continue to limit wider use.

However, glucose control is only part of the story. The cardiovascular and kidney results associated with this drug class in other populations have changed how clinicians think about SGLT inhibitors.

In type 2 diabetes, chronic kidney disease, and heart failure, SGLT inhibition has demonstrated benefits that extend beyond lowering glucose. For example, major trials have reported reductions in heart failure hospitalization and progression of kidney disease. Moreover, these benefits can persist even when the glucose-lowering effect becomes relatively modest.

That creates a compelling hypothesis. Could people with type 1 diabetes eventually receive similar organ protection?

For now, the evidence does not provide a definitive answer. Most trials of SGLT inhibitors in type 1 diabetes were designed around glycemic outcomes rather than major cardiovascular or renal endpoints. Therefore, benefits demonstrated in type 2 diabetes or broader CKD populations cannot simply be assumed to apply equally to type 1 diabetes.

The Heart and Kidney Case for SGLT Inhibition

The cardiovascular argument is especially intriguing because people living with type 1 diabetes can develop substantial long-term cardiovascular risk. Consequently, therapies that could reduce that burden would address an important unmet need.

Researchers are increasingly asking whether SGLT inhibition could provide cardiovascular protection beyond improvements in A1C. Recent analyses of randomized trials have found improvements in several cardiometabolic measures with SGLT2 inhibitor therapy in type 1 diabetes. However, the available trials do not establish the kind of cardiovascular outcome evidence already available for other populations.

The kidney rationale is similarly important. SGLT inhibitors alter renal hemodynamics and have shown substantial kidney protection in chronic kidney disease trials. In DAPA-CKD, for example, dapagliflozin reduced the risk of the primary kidney and cardiovascular composite outcome. EMPA-KIDNEY also demonstrated a reduced risk of kidney disease progression or cardiovascular death with empagliflozin. The American Diabetes Association’s guidance on chronic kidney disease and diabetes discusses the growing role of SGLT2 inhibitors in kidney protection.

Yet these results should not be interpreted as proof of equivalent protection in type 1 diabetes. Dedicated trials involving people with type 1 diabetes and sufficient cardiovascular or kidney risk would be needed to determine whether the benefits outweigh treatment-specific hazards.

That distinction matters. The question is no longer simply whether an SGLT inhibitor can lower A1C in type 1 diabetes. Instead, researchers need to determine whether meaningful cardiorenal protection can justify the additional safety burden.

Why DKA Remains the Central Safety Barrier

The most important safety concern with SGLT2 inhibitors in type 1 diabetes is diabetic ketoacidosis. According to the American Diabetes Association’s 2026 Standards of Care, SGLT inhibitor-associated DKA occurs in approximately 4% of people with type 1 diabetes, with risk estimated at 5 to 17 times higher than among people with type 1 diabetes not receiving these drugs. The ADA also states that SGLT2 inhibitors are not approved for use in people with type 1 diabetes.

A recent meta-analysis reinforces the concern. Although SGLT2 inhibitors improved A1C and body weight, investigators found a significantly higher DKA risk, with a reported relative risk of 4.45 compared with placebo.

Moreover, SGLT-associated DKA can be unusually difficult to recognize. Because the medication promotes urinary glucose excretion, ketoacidosis may develop without the severe hyperglycemia traditionally associated with DKA. This condition is often called euglycemic DKA.

As a result, a patient may experience nausea, vomiting, abdominal pain, fatigue, or rapid breathing while glucose readings appear less alarming than expected. That can delay recognition and treatment.

Several circumstances may increase risk. These include illness, dehydration, fasting, very-low-carbohydrate diets, excessive alcohol intake, large insulin-dose reductions, and insulin pump or infusion-set failures.

Therefore, simply telling patients to monitor glucose more closely is not enough. Ketone monitoring becomes a critical part of any proposed safety strategy. An international consensus on DKA risk management with SGLT inhibitors has emphasized careful patient selection, ketone monitoring, education, and appropriate medication interruption.

What Would Make Broader SGLT2 Inhibitor Use More Realistic?

Broader use of SGLT inhibitors for type 1 diabetes would likely require more than another modest improvement in A1C. Researchers need convincing evidence that cardiovascular or kidney benefits are substantial enough to outweigh DKA risk.

First, future trials should identify which patients are most likely to benefit. Someone with established CKD or very high cardiovascular risk may have a different benefit-risk calculation than a younger person without cardiorenal disease.

Second, researchers need better tools for predicting DKA. Current risk factors are useful, but they cannot perfectly identify who will develop ketoacidosis.

Third, practical ketone-monitoring strategies must become easier to follow. International consensus recommendations have emphasized blood ketone monitoring, careful patient selection, conservative insulin adjustments, and temporarily withholding SGLT inhibitors during illness, fasting, dehydration, or procedures.

Dose may also matter. Earlier research with empagliflozin found that a 2.5 mg experimental dose produced a DKA rate closer to placebo than the 10 mg and 25 mg doses studied. Therefore, future research could explore whether lower doses preserve enough benefit while reducing ketoacidosis risk.

Finally, dedicated cardiorenal outcome trials would be particularly valuable. Without them, clinicians are forced to extrapolate from populations whose underlying diabetes biology and DKA risk differ significantly.

Conclusion

SGLT inhibitors have established an impressive role in protecting the heart and kidneys across several high-risk populations. Consequently, interest in extending those benefits to type 1 diabetes is understandable.

Still, using SGLT inhibitors in type 1 diabetes presents a unique risk-benefit challenge. Modest improvements in A1C, weight, and other metabolic measures are meaningful, but increased DKA risk cannot be ignored. Current ADA guidance notes that SGLT2 inhibitors are not approved for people with type 1 diabetes.

The next chapter will therefore depend on better evidence. Researchers need to establish whether true cardiovascular and renal protection occurs in type 1 diabetes, identify patients with the greatest potential benefit, and develop reliable strategies that reduce DKA risk to an acceptable level.

Until those questions are answered, the remarkable success of SGLT inhibition elsewhere remains both an opportunity and a reminder of why type 1 diabetes is different.

Frequently Asked Questions

Are SGLT inhibitors approved for type 1 diabetes in the United States?

No. The American Diabetes Association’s 2026 Standards of Care states that SGLT2 inhibitors are not approved for use in people with type 1 diabetes. Their use in this population therefore should not be viewed as routine therapy.

Why are researchers interested in SGLT inhibitors for type 1 diabetes?

Clinical trials have shown improvements in A1C and body weight. In addition, the substantial heart and kidney benefits seen with SGLT inhibition in other populations have created interest in whether similar organ protection might occur in type 1 diabetes.

Why do SGLT inhibitors increase DKA risk?

SGLT inhibition increases urinary glucose loss and can allow glucose levels to remain relatively modest even when insulin availability is inadequate. Reduced insulin, illness, fasting, dehydration, and other factors can then promote ketone production and ketoacidosis.

What is euglycemic DKA?

Euglycemic DKA is ketoacidosis that develops without the degree of severe hyperglycemia commonly expected with traditional DKA. Because glucose readings can appear deceptively reassuring, ketone testing and recognition of symptoms become especially important.

Could SGLT inhibitors eventually have a role in type 1 diabetes?

Possibly, but stronger evidence is needed. Future studies would need to demonstrate clinically important cardiovascular or kidney benefits while also showing that patient selection, dosing, ketone monitoring, and other risk-mitigation strategies can make DKA risk acceptably low.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.